Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lipocine Inc. (LPCN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, including current reports, quarterly and annual reports, and exhibits filed with the U.S. Securities and Exchange Commission. According to recent Form 8‑K filings, Lipocine uses these reports to announce clinical and corporate developments such as Phase 3 trial progress, data presentations, and financial results.
Current reports on Form 8‑K have documented events including enrollment and interim safety milestones in the Phase 3 clinical trial of LPCN 1154 for postpartum depression, presentation of LPCN 2101 data at the American Epilepsy Society annual meeting, and presentation of LPCN 2401 clinical data at ObesityWeek. Other 8‑K filings reference updated corporate presentations and the company’s participation in investor conferences, as well as press releases announcing quarterly financial and operational results.
Lipocine’s periodic reports on Forms 10‑Q and 10‑K, referenced in its press releases, provide more detailed information on revenues from TLANDO licensing and royalties, research and development expenses related to candidates such as LPCN 1154 and LPCN 2401, general and administrative costs, and cash and investment balances. These filings also include risk factor discussions and forward‑looking statements that describe uncertainties around clinical trials, regulatory approvals, partnering, and commercialization.
On Stock Titan, investors can review Lipocine’s SEC filings in one place and use AI‑powered summaries to interpret dense disclosures. Real‑time updates from EDGAR allow users to see new 8‑K, 10‑Q, and 10‑K filings as they appear, while Form 4 and related insider transaction reports can be accessed to monitor trading by Lipocine’s officers and directors. AI tools help highlight key points from lengthy documents, such as clinical program updates, revenue drivers from TLANDO agreements, and changes in operating expenses, giving a clearer view of how Lipocine’s oral drug development strategy is reflected in its official regulatory record.
Lipocine Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 3, 2026 in Salt Lake City. Stockholders will elect four directors, ratify Tanner LLC as auditor for the year ending December 31, 2026, and cast an advisory “say‑on‑pay” vote on executive compensation.
The company also seeks approval to amend and restate its 2014 Stock and Incentive Plan, raising the annual individual award limit from 25,000 to 100,000 shares and increasing the total shares authorized for issuance under the plan from 600,000 to 1,000,000. As of the April 6, 2026 record date, 8,025,115 common shares were outstanding, and the Board unanimously recommends voting in favor of all proposals.
Lipocine Inc. reported that on April 16, 2026, Dr. Spyros Papapetropoulos resigned from its Board of Directors effective immediately. He had served since 2022 as Chairman, Lead Independent Director, and a member of the Board’s compensation committee.
The company stated that Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on Lipocine’s strategic direction. On April 20, 2026, the Board appointed R. Dana Ono as the new Chairman of the Board and Lead Independent Director, ensuring continuity in independent board leadership.
Lipocine Inc. director John W. Higuchi increased his stake by purchasing 40,000 shares of common stock in an open-market transaction. He paid $2.03 per share, for a total of about $81,200. After this purchase, he directly holds 203,797 Lipocine shares.
Lipocine Inc. director John W. Higuchi reported an open-market purchase of company stock. On April 6, 2026, he bought 123,000 shares of Lipocine common stock at $2.05 per share, increasing his direct ownership to 163,797 shares after the transaction.
Lipocine Inc. director and Chief Executive Officer Mahesh V. Patel reported an open-market purchase of company stock. On this date, he bought 25,000 shares of Lipocine common stock at $2.03 per share. Following this transaction, he directly owns 160,679 common shares of Lipocine.
Lipocine Inc. Chief Executive Officer Mahesh V. Patel purchased 25,000 shares of Lipocine common stock in an open-market transaction at $2.02 per share on April 2, 2026. Following this trade, he directly owns 135,679 shares of Lipocine common stock.
Lipocine Inc. reported topline Phase 3 results for LPCN 1154, an oral brexanolone, in postpartum depression. The study did not meet its primary endpoint, as LPCN 1154 failed to show a statistically significant improvement in HAM-D total score versus placebo at hour 60 in the full analysis set.
Despite missing the primary endpoint, LPCN 1154 was well tolerated, with a favorable safety profile supporting outpatient use and no treatment-related serious adverse events, excessive sedation, loss of consciousness, or treatment-related discontinuations. A post hoc analysis of patients with a history of psychiatric conditions showed signals that may inform a potential development path. Based on these data, Lipocine has applied for breakthrough therapy and fast track designations and plans to preserve capital while engaging stakeholders to evaluate options, which may include further LPCN 1154 work, other pipeline programs, or strategic transactions.
Lipocine Inc. reported full-year 2025 results with revenue of $2.0 million and a net loss of $9.6 million, compared with revenue of $11.2 million and net income of $8,352 in 2024. The revenue decline mainly reflects lower license revenue, partly offset by higher TLANDO royalty revenue.
Research and development expenses rose to $8.6 million from $7.4 million as the company increased clinical and personnel spending, while general and administrative expenses declined to $3.8 million from $5.0 million due to lower professional, legal, tax and insurance costs. As of December 31, 2025, Lipocine held $14.9 million in unrestricted cash, cash equivalents and marketable investment securities, which increased to approximately $24.7 million as of March 6, 2026, primarily from an at-the-market stock offering.
The company highlighted progress in its pipeline, including candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms and preterm birth prevention, alongside TLANDO, an FDA-approved oral testosterone product.
Lipocine Inc. is a clinical-stage biopharmaceutical company using a proprietary oral lipid-based delivery platform to improve absorption of hard‑to‑deliver drugs, with a focus on CNS disorders, liver disease, and hormone therapies.
The company has transformed its testosterone replacement therapy franchise into a licensing model. Verity holds exclusive rights to TLANDO in the U.S. and Canada, paying Lipocine $2.5 million on signing, $5 million in February 2024, $2.5 million in December 2024 and $1 million in January 2026, plus up to $259 million in potential milestones and tiered royalties of 12%–18%. Additional TLANDO licenses cover South Korea (SPC), Gulf Cooperation Council countries (Pharmalink) and Brazil (Aché), each with upfront fees, milestones and supply arrangements.
Lipocine’s lead CNS asset, LPCN 1154 for postpartum depression, has completed enrollment and last patient visit in a Phase 3 trial, with data expected in April 2026 to support a planned 505(b)(2) NDA. Other neuroactive steroid programs target major depressive disorder, epilepsy and essential tremor. In liver disease, LPCN 1148 showed Phase 2 proof‑of‑concept in decompensated cirrhosis with improved muscle mass and fewer decompensation events. Research and development spending was $8.6 million in 2025 versus $7.4 million in 2024. As of March 9, 2026, Lipocine had 7,299,687 common shares outstanding and reported a $16.4 million aggregate market value of non‑affiliate holdings as of June 30, 2025.